Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia

被引：0
|
作者：
Van Wart, Scott [1 ]
Shoaf, Susan [2 ]
Mallikaarjun, Suresh [2 ]
Mager, Donald [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] Otsuka, Rockville, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-06
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [31] Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat
    Miyazaki, M
    Sawada, S
    Nishide, T
    Iwanaga, K
    Morimoto, K
    Kakemi, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (01) : 87 - 96
  • [32] Pharmacokinetic-pharmacodynamic (Pk-Pd) modeling of entecavir: Prediction of log decrease in hepatitis B viral load
    Fiske, W
    Olsen, S
    Yan, JH
    Grasela, D
    Phillips, L
    Owen, J
    HEPATOLOGY, 2002, 36 (04) : 631A - 631A
  • [33] Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs
    Papich, Mark G.
    VETERINARY MICROBIOLOGY, 2014, 171 (3-4) : 480 - 486
  • [34] Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of chemotherapy-induced neutropenia (CIN) in patients treated with CPX-351
    Cook, Sarah F.
    Wang, Qi
    Mager, Donald E.
    Van Wart, Scott A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S100 - S101
  • [35] Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling and Trial Simulation for Selection of Optimal Dose of Fedratinib (SAR302503)
    Liu, Li
    Xu, Christine
    Su, Yaming
    Ma, Lei
    Quan, Hui
    Kanamaluru, Vanaja
    Shun, Zhenming
    Deutsch, Paul
    Zaks, Tal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S18 - S18
  • [36] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING IN NON-STEADY-STATE STUDIES AND ARTERIOVENOUS DRUG CONCENTRATION DIFFERENCES
    GUMBLETON, M
    OIE, S
    VEROTTA, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) : 389 - 400
  • [37] Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats
    Kobuchi, Shinji
    Ito, Yukako
    Hayakawa, Taro
    Nishimura, Asako
    Shibata, Nobuhito
    Takada, Kanji
    Sakaeda, Toshiyuki
    XENOBIOTICA, 2015, 45 (01) : 19 - 28
  • [38] A PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODEL WITH PREDICTIVE BIOMARKER TO SIMULATE COLORECTAL TUMOR GROWTH IN RATS AFTER 5-FLUOROURACIL TREATMENT
    Kobuchi, Shinji
    Ito, Yukako
    Takada, Kanji
    DRUG METABOLISM REVIEWS, 2014, 45 : 221 - 222
  • [39] Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of etanercept in patients with juvenile rheumatoid arthritis (JRA) using a dichotomous clinical endpoint.
    Yim, D
    Zhou, H
    Peck, CC
    Lee, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P92 - P92
  • [40] Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of serdemeten-induced QTc effects in a first-in-human study
    Huntjens, D. R.
    Van Beijsterveldt, L.
    Kraljevic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345